Open Access
Med Sci (Paris)
Volume 38, Number 11, Novembre 2022
Page(s) 873 - 877
Section Nouvelles
Published online 30 November 2022
  1. Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol 2016 ; 17 : e254–e262. [Google Scholar]
  2. Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies 2020; 20; 9 : E34. [CrossRef] [PubMed] [Google Scholar]
  3. Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab: The world’s first oncology monoclonal antibody therapy. Front Oncol 2018 ; 8 : 163. [CrossRef] [PubMed] [Google Scholar]
  4. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008 ; 14 : 358: 676–688. [Google Scholar]
  5. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I : Molecular mechanisms of activation and regulation. Front Immunol 2015 ; 6 : 262. [PubMed] [Google Scholar]
  6. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol 2008 ; 8 : 34–47. [Google Scholar]
  7. Thorley-Lawson DA. EBV persistence: Introducing the virus. Curr Top Microbiol Immunol 2015 ; 390 : 151–209. [PubMed] [Google Scholar]
  8. Ogolla S, Daud II, Asito AS, et al. Reduced transplacental transfer of a subset of Epstein-Barr virus-specific antibodies to neonates of mresearch-articles infected with Plasmodium falciparum malaria during pregnancy. Clin Vaccine Immunol 2015 ; 22 : 1197–1205. [CrossRef] [PubMed] [Google Scholar]
  9. Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell 2018 ; 9 : 63–73. [Google Scholar]
  10. Gamain B, Brousse C, Rainey NE, et al. BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells. Sci Adv 2022; 8 : eabl4363. [Google Scholar]
  11. Joubert S, Dodelet V, Béliard R, Durocher Y. La bioproduction des anticorps monoclonaux. Med Sci (Paris) 2019 ; 35 : 1153–1159. [Google Scholar]
  12. Catros V. Les CAR-T cells, des cellules tueuses spécifiques d’antigènes tumoraux - De nouvelles générations pour le traitement des tumeurs solides. Med Sci (Paris) 2019 ; 35 : 316–326. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.